User profiles for Frans V. Suurs
 | Frans V. SuursUniversity of Oslo Verified email at medisin.uio.no Cited by 411 |
[HTML][HTML] A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to cancer.. For
use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of …
use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of …
Development and evaluation of interleukin-2–derived radiotracers for PET imaging of T cells in mice
Recently, N-(4- 18 F-fluorobenzoyl)-interleukin-2 ( 18 F-FB-IL2) was introduced as a PET
tracer for T cell imaging. However, production is complex and time-consuming. Therefore, we …
tracer for T cell imaging. However, production is complex and time-consuming. Therefore, we …
89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake
KL Moek, SJH Waaijer, IC Kok, FV Suurs… - Clinical Cancer …, 2019 - AACR
Purpose: Biodistribution of bispecific antibodies in patients is largely unknown. We therefore
performed a feasibility study in 9 patients with advanced gastrointestinal adenocarcinomas …
performed a feasibility study in 9 patients with advanced gastrointestinal adenocarcinomas …
[HTML][HTML] Fluorescent image-guided surgery in breast cancer by intravenous application of a quenched fluorescence activity-based probe for cysteine cathepsins in a …
Purpose The reoperation rate for breast-conserving surgery is as high as 15–30% due to
residual tumor in the surgical cavity after surgery. In vivo tumor-targeted optical molecular …
residual tumor in the surgical cavity after surgery. In vivo tumor-targeted optical molecular …
The Biodistribution of a Cd3 and Epcam Bispecific T-cell Engager is driven by the Cd3 arm
FV Suurs, G Lorenczewski, S Stienen… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Bispecific T-cell engager (BiTE) molecules are designed to engage and activate cytotoxic T
cells to kill tumor cells. Little is known about their biodistribution in immunocompetent settings…
cells to kill tumor cells. Little is known about their biodistribution in immunocompetent settings…
89Zr-3, 2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin-targeted 227Th-conjugate therapy in mice
The mesothelin (MSLN)-targeted 227 Th conjugate is a novel α-therapy developed to treat
MSLN-overexpressing cancers. We radiolabeled the same antibody–chelator conjugate with …
MSLN-overexpressing cancers. We radiolabeled the same antibody–chelator conjugate with …
[HTML][HTML] Radiolabeled monoclonal antibody against colony-stimulating factor 1 receptor specifically distributes to the spleen and liver in immunocompetent mice
SJH Waaijer, FV Suurs, CS Hau, K Vrijland… - Frontiers in …, 2021 - frontiersin.org
Macrophages can promote tumor development. Preclinically, targeting macrophages by
colony-stimulating factor 1 (CSF1)/CSF1 receptor (CSF1R) monoclonal antibodies (mAbs) …
colony-stimulating factor 1 (CSF1)/CSF1 receptor (CSF1R) monoclonal antibodies (mAbs) …
Mesothelin/CD3 Half-Life–Extended Bispecific T-Cell Engager Molecule Shows Specific Tumor Uptake and Distributes to Mesothelin and CD3-Expressing Tissues
FV Suurs, G Lorenczewski, JM Bailis… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Bispecific T-cell engager (BiTE) molecules exert antitumor activity by binding one arm to
CD3 on cytotoxic T cells and the other arm to a tumor-associated antigen. Methods: We …
CD3 on cytotoxic T cells and the other arm to a tumor-associated antigen. Methods: We …
PET imaging shows dose-dependent pharmacokinetics of a 89Zr-labeled mesothelin/CD3 half-life extended bispecific T-cell engager molecule in a syngeneic mouse …
FV Suurs, G Lorenczewski, JM Bailis, S Stienen… - Cancer Research, 2020 - AACR
BiTE ® (bispecific T cell engager) immune therapy consists of two connected single-chain
variable fragments, one targeting T-cells via CD3, and one targeting the tumor via a tumor-…
variable fragments, one targeting T-cells via CD3, and one targeting the tumor via a tumor-…
SPECT-imaging guided development and evaluation of targeted alpha therapy (TAT) for colorectal liver metastasis
FV Suurs, A Kristian, G Petros, YZ Feng, KG Fleten… - Cancer Research, 2022 - AACR
BACKGROUND: Only a small fraction of patients with colorectal liver metastases (CLM) is
eligible for curative resection, and novel treatment options are highly needed. The high linear-…
eligible for curative resection, and novel treatment options are highly needed. The high linear-…